MNKD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
MannKind Corp (MNKD) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong growth potential, upcoming FDA decisions, and positive analyst ratings outweigh the short-term technical weakness and insider neutrality. The stock's current price and long-term catalysts make it a solid entry point.
The stock's MACD is negative and expanding, indicating bearish momentum. RSI is neutral at 41.966. However, the moving averages are bullish (SMA_5 > SMA_20 > SMA_200), suggesting an overall upward trend. The stock is trading near its support level (S1: 5.548), which could act as a cushion for further downside.
FDA decision on Afrezza label update on January 23 and pediatric use application on May
Enrollment of the first patient in the INHALE-1ST clinical study for Afrezza in children.
Positive analyst ratings with price targets of $9 and $11, indicating significant upside potential.
Revenue growth of 17.20% YoY in Q3 2025.
Hedge funds are selling, with a 337.78% increase in selling activity over the last quarter.
Net income and EPS have declined YoY (-30.87% and -25.00%, respectively).
Short-term technical indicators like MACD and RSI do not show strong bullish momentum.
In Q3 2025, MannKind reported a revenue increase of 17.20% YoY to $82.13M, showcasing strong growth. However, net income dropped by 30.87% YoY to $7.99M, and EPS fell by 25.00% YoY to $0.03. Gross margin improved to 79.42%, up 6.30% YoY, indicating operational efficiency.
Analysts are bullish on MannKind, with H.C. Wainwright reiterating a Buy rating and an $11 price target, and Truist initiating coverage with a Buy rating and a $9 price target. Analysts highlight the company's strong pipeline, recent acquisitions, and growth potential.
